New data presented at ats 2024 show the potential of tezspire® to help patients living with copd

Late-breaking results from the phase 2a course trial illustrate tezspire's impact on copd exacerbations in patients with a broad range of eosinophil levels thousand oaks, calif. , may 19, 2024 /prnewswire/ -- amgen (nasdaq:amgn) and astrazeneca today announced the results of the phase 2a course trial evaluating tezspire® (tezepelumab-ekko) in people with moderate to very severe chronic obstructive pulmonary disease (copd) with a broad range of baseline blood eosinophil counts (bec) irrespective of emphysema, chronic bronchitis or smoking status.
ATS Ratings Summary
ATS Quant Ranking